Fingolimod in the treatment of schizophrenia
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20090117001556N137
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of schizophrenia based on DSM-5
Minimum score of 60 based on PANSS
Age range: 18-60 years old
At least, 2 years have passed since the onset of the disorder
Exclusion Criteria
Diagnosis of another disorder in axis II
Existence of a significant neurological or organic disease
IQ less than 70 based on interviewer clinical suspicion
Substance/drug dependence during the last 6 months (except nicotine and caffeine)
Use of antipsychotics during past 1 week or long-term antipsychotics during past 1 month
Receiving ECT during the last 2 weeks
Abnormal endocrine activity
Abnormal kidney and liver function
History of thrombosis and emboli
History of abnormal bleeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method